Respiratory Syncytial Virus Monoclonal Antibodies for Rapid Antigen LFA Development
Respiratory Syncytial Virus (RSV) is a single-stranded RNA virus of the family Pneumoviridae and the leading cause of acute lower respiratory tract infection (ALRTI) in infants and young children worldwide. RSV infects virtually all children by age 2, with approximately 33 million episodes of RSV-associated ALRTI in children under 5 annually (Shi et al., The Lancet, 2017). RSV is also a significant respiratory pathogen in elderly adults and immunocompromised patients, causing substantial morbidity and mortality.
RSV exists as two major subtypes — RSV-A and RSV-B — which co-circulate during seasonal epidemics (typically October–March in the northern hemisphere). Accurate and rapid differentiation of RSV from other respiratory pathogens (influenza, SARS-CoV-2, parainfluenza) is essential for appropriate antiviral treatment with nirsevimab, palivizumab prophylaxis for high-risk infants, and hospital infection control measures.
Sekbio's RSV antibody pair (S03-RSV-22 capture + S03-RSV-23 detection) targets the highly conserved RSV nucleoprotein (N protein), enabling sensitive and specific RSV antigen detection across both RSV-A and RSV-B subtypes in a 15-minute lateral flow assay from nasopharyngeal swab samples.
Capture and detection antibodies targeting RSV nucleoprotein for complete LFA sandwich immunoassay system development.
| Catalog No. | Product Name | Target | Role | Isotype | Purity | Platform | Storage |
|---|---|---|---|---|---|---|---|
| S03-RSV-22 | Mouse Anti-RSV mAb (Capture) | RSV N Protein | Capture | Mouse IgG | >90% SDS-PAGE | LFA | +2°C to +8°C |
| S03-RSV-23 | Mouse Anti-RSV mAb (Detection) | RSV N Protein | Detection | Mouse IgG | >90% SDS-PAGE | LFA | +2°C to +8°C |
All products supplied in PBS pH 7.2–7.4. MOQ 1 mg. OEM quantities (10 mg–gram scale) available. Contact info@sekbio.com for bulk pricing and lot availability.
Engineered for the sensitivity, specificity, and batch consistency required in LFA RSV antigen rapid test manufacturing.
S03-RSV-22 and S03-RSV-23 target the RSV nucleoprotein (N protein), which is >95% conserved between RSV-A and RSV-B subtypes. This ensures detection of both major circulating strains without subtype-specific performance differences in nasopharyngeal samples.
The S03-RSV-22 / S03-RSV-23 pair is selected for efficient colloidal gold and fluorescent particle conjugation with stable signal generation in lateral flow format. Pre-screened for non-overlapping epitopes to maximise sandwich complex formation at the test line.
Manufactured under ISO 13485 QMS with inter-batch CV <10%. Each lot is tested for appearance, purity, concentration, and LFA functional performance before release, ensuring consistent test line intensity and sensitivity across production batches.
RSV antigen is detected in nasopharyngeal swab eluate. Sekbio's RSV antibody pair is validated for performance in the swab buffer matrices commonly used in clinical LFA RSV rapid test kits, accounting for mucus components and swab preservatives.
RSV antibodies can be integrated into multi-analyte respiratory panels alongside Sekbio's influenza A/B and other respiratory pathogen antibodies. Supports development of combination RSV + Flu + COVID-19 multiplex lateral flow devices for comprehensive respiratory triage.
ISO 13485-compliant manufacturing in Shenzhen, China. MOQ 1 mg for R&D; gram-scale OEM production supply available. Sekbio exports RSV antibodies to Africa, Southeast Asia, the Middle East, and South America for rapid test manufacturers supplying high-burden RSV markets.
RSV antibody pair validated for rapid antigen test development, combination respiratory panels, and OEM kit manufacturing.
RSV is the #1 cause of hospitalisation in infants under 12 months in high-income countries. Rapid LFA antigen tests using the S03-RSV-22 / S03-RSV-23 pair enable 15-minute point-of-care RSV diagnosis in pediatric emergency departments, guiding admission decisions and cohorting of RSV-positive infants to prevent nosocomial spread.
RSV causes significant morbidity in adults over 65 and in immunocompromised patients (organ transplant, haematological malignancy). Rapid RSV antigen testing in these populations guides antiviral prophylaxis decisions (palivizumab, nirsevimab, ribavirin) and hospital infection control, particularly relevant in care home and haematology unit outbreaks.
RSV commonly co-circulates with influenza A, influenza B, and SARS-CoV-2 during winter respiratory seasons. Sekbio RSV antibodies can be incorporated into multiplex LFA strips or FIA readers alongside influenza and COVID-19 antibody pairs from Sekbio's product catalog, enabling a single combination respiratory triage test for rapid differential diagnosis.
IVD manufacturers in Africa, Southeast Asia, and the Middle East developing CE-marked or locally registered RSV rapid tests can source the S03-RSV-22 / S03-RSV-23 pair from Sekbio with ISO 13485 batch documentation for regulatory submissions. Contact info@sekbio.com or visit our Rapid Test page for OEM finished product options.
Technical and commercial questions from IVD R&D engineers and procurement teams.
Respiratory Syncytial Virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants, responsible for ~33 million ALRTI episodes in children under 5 annually (Shi et al., Lancet 2017). Rapid LFA antigen detection enables bedside RSV diagnosis in 15 minutes without laboratory infrastructure, guiding antiviral treatment, prophylaxis, and infection control decisions in hospitals and care homes.
Sekbio supplies: S03-RSV-22 (Mouse IgG capture antibody against RSV N protein) and S03-RSV-23 (Mouse IgG detection antibody against RSV N protein). Both are available from MOQ 1 mg with ISO 13485-compliant lot documentation.
S03-RSV-22 / S03-RSV-23 is validated for lateral flow assay (LFA) format for RSV rapid antigen detection in nasopharyngeal swab eluate. The pair is optimised for colloidal gold and fluorescent particle conjugation used in POCT rapid test devices.
Yes. Both antibodies target the RSV nucleoprotein (N protein), which is >95% conserved between RSV-A and RSV-B. This ensures cross-reactive detection of both major circulating RSV subtypes without clone-specific performance gaps.
Both RSV antibodies are affinity-purified with purity >90% by SDS-PAGE. Storage: +2°C to +8°C for working aliquots; −20°C for long-term storage. Shelf life 3 years. Certificate of Analysis provided with each lot.
Yes. Sekbio supplies RSV, influenza A/B, and other respiratory pathogen antibody pairs, enabling multi-analyte combination LFA development from a single ISO 13485-certified source. Custom RSV clone development and recombinant antibody engineering are also available. Contact info@sekbio.com or visit our Platforms page to discuss your RSV panel requirements.
Request the full technical datasheet, RSV antibody pair specifications, or discuss OEM supply with our team.